News
The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.
Inside one of those nondescript rooms last week, the Advisory Committee on Immunization Practices (ACIP), an independent panel that makes vaccine recommendations to the Centers for Disease Control and ...
Inside one of those nondescript rooms last week, the Advisory Committee on Immunization Practices (ACIP), an independent ...
That whole meeting was a travesty,” says Fiona Havers, a physician and epidemiologist. After the ACIP firings, Havers ...
Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...
The CDC panel voted against an ingredient that the anti-vaccine movement has long targeted, while Arcadia was acquired by ...
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
8d
Zacks Investment Research on MSNModerna Stock Gains on Encouraging Flu Vaccine DataModerna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy ...
The preservative is in a small share of flu shots and has been studied for decades. Experts say it’s safe — despite Kennedy’s long opposition.
8d
Clinical Trials Arena on MSNModerna’s mRNA flu shot outperforms current standard at Phase IIIThe trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.
A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results